Upregulation of serum miR-103 predicts unfavorable prognosis in patients with colorectal cancer.

OBJECTIVE: Circulating microRNAs (miRNAs) have been reported as biomarkers for the early detection of colorectal cancer (CRC). We aimed at evaluating the diagnostic and prognostic value of serum miR-103 in CRC patients.

PATIENTS AND METHODS: Quantitative reverse-transcription PCR (qRT-PCR) was applied to measure the miR-103 levels in blood samples of 96 patients and 60 controls.

RESULTS: Our results demonstrated that serum miR-103 was overexpressed in CRC subjects and the receiver operating characteristic (ROC) curve analysis showed that serum miR-103 could differentiate CRC cases from controls with relatively high accuracy. In addition, serum miR-103 level was more frequently detected in CRC patients with positive lymph node metastasis, distant metastasis and advanced tumor stage. Moreover, serum miR-103 levels in 23 postoperative blood samples were lower than paired preoperative plasma specimens, and serum miR-103 levels were re-elevated in seven patients at recurrence. Furthermore, serum miR-103 was significantly correlated with worse clinical factors, as well as poorer recurrence-free survival or overall survival. Finally, multivariate analysis confirmed that serum miR-103 was an independent prognostic marker for CRC.

CONCLUSIONS: Taken together, serum miR-103 might be a promising biomarker for diagnosis and prognosis of CRC.